Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of a Pentavalent Rotavirus Vaccine (BRV-PV) Against Severe Rotavirus Gastroenteritis in Niger

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. aged 6-8 weeks at the time of inclusion~2. able to swallow and no history of vomiting within 24 hours~3. resident in Madarounfa Health District and within the catchment area of the central health facility~4. intending to remain in the study area for 2 years~5. parent/guardian providing written informed consent~Exclusion Criteria:~Any of the following will exclude an infant from randomization in the study:~1. known history of congenital abdominal disorders, intussusception, or abdominal surgery~2. receipt of intramuscular, oral, or intravenous corticosteroid treatment within 2 wks~3. receipt or planned administration of a blood transfusion or blood products, including immunoglobulins~4. any known immunodeficiency condition~5. any serious medical condition~6. any other condition in which, in the judgment of the investigator, would interfere with or serves as a contraindication to protocol adherence or the parent/guardian's ability to give informed consent

- Gender: ALL
- Minimum Age: 6 Weeks
- Maximum Age: 2 Years
- Healthy Volunteers: t

Study Arms:
- Rotavirus vaccine (BRV-PV) (Type: EXPERIMENTAL): Live attenuated bovine-human \[UK\] reassortant rotavirus vaccine manufactured by the Serum Institute of India, Limited (SIIL). The pentavalent vaccine (BRV-PV) contains rotavirus serotypes G1, G2, G3, G4, and G9 (≥5.6 log10 FFU/serotype/dose). The vaccine is in lyophilized form and supplied with 2.5 ml of citrate bicarbonate buffer that is added for reconstitution just before oral administration.
- Placebo (Type: PLACEBO_COMPARATOR): Same constituents as the active vaccine but without the viral antigens; manufactured by SIIL.

Based on this trial design, predict the completion outcome and termination type (if applicable).